Compare BCRX & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCRX | NUV |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1995 | N/A |
| Metric | BCRX | NUV |
|---|---|---|
| Price | $8.26 | $9.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $20.82 | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 506.4K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.96% |
| EPS Growth | ★ 381.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,186,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.00 | $8.45 |
| 52 Week High | $11.31 | $9.26 |
| Indicator | BCRX | NUV |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 39.86 |
| Support Level | $7.94 | $8.89 |
| Resistance Level | $8.68 | $9.05 |
| Average True Range (ATR) | 0.46 | 0.06 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 23.34 | 18.18 |
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.